Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

BRAF Alterations as Therapeutic Targets in Non-Small-Cell Lung Cancer.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Oct 2015

Nguyen-Ngoc Tu, Bouchaab Hasna, Adjei Alex A, Peters Solange

Abstract excerpt

BACKGROUND: Several subsets of non-small-cell lung cancer (NSCLC) are defined by molecular alterations acting as tumor drivers, some of them being currently therapeutically actionable. The rat sarcoma (RAS)-rapidly accelerated fibrosarcoma (RAF)-mitogen-activated protein/extracellular signal-regulated kinase kinase (MEK)-extracellular signal-regulated kinase (ERK) pathway constitutes an attractive potential...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to BRAF gene

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Lung Neoplasms

Share to Molecular Targeted Therapy

Share to Mutation

Share to Proto-Oncogene Proteins B-raf

Source

Identifiers

PMID: 26301799
DOI: 10.1097/JTO.0000000000000644

Genes

BRAF

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BRAF Alterations as Therapeutic Targets in Non-Small-Cell Lung Cancer.PMID 26301799Read ↗

Targeting BRAF-mutant non-small cell lung cancer: Current status and future directions.Semantic proximity Read ↗

Targeting BRAF-Mutant Non-Small Cell Lung Cancer: From Molecular Profiling to Rationally Designed Therapy.Semantic proximity Read ↗

RAF and MEK Inhibitors in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Ongoing progress in BRAF-mutated non-small cell lung cancer.Semantic proximity Read ↗

BRAF mutant non-small cell lung cancer and treatment with BRAF inhibitors.Semantic proximity Read ↗

How far we have come targeting BRAF-mutant non-small cell lung cancer (NSCLC).Semantic proximity Read ↗

Pathways and targeting avenues of BRAF in non-small cell lung cancer.Semantic proximity Read ↗

Advances in anti-BRAF therapies for lung cancer.Semantic proximity Read ↗

BRAF mutations in non-small cell lung cancer: has finally Janus opened the door?Semantic proximity Read ↗

Dabrafenib and trametinib for the treatment of non-small cell lung cancer.Semantic proximity Read ↗

Targeting the MEK signaling pathway in non-small cell lung cancer (NSCLC) patients with RAS aberrations.Semantic proximity Read ↗

[Progress of BRAF Gene Alteration in Non-small Cell Lung Cancer].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.